Although tumor-derived MDSCs from anti-PD-L1 treated Hepa 1-6-bearing mice showed the capacity to inhibit T cell proliferation as those from DMSO-treated mice, tumor-derived MDSCs from the combination therapy group had a further reduced capacity to block T cell proliferation compared to ART therapy group (Figure 5(o)). The gene discussed is CD274; the disease is neoplasm.